iShares China Large-Cap ETF

Recent news

• Waters Corporation Announces FDA Clearance Of BD BACTEC FXI Culture System, Advancing Faster Sepsis Detection In U.S. Laboratories
  Benzinga · 2026/6/3
• Guosen Securities: FXI inhibitors are expected to become the next generation of anticoagulant drugs. It is recommended to pay attention to Hengrui Pharma (600276.SH).
  Zhitong Finance · 2025/12/15
• Rebio Bio is making a final push to the Hong Kong Stock Exchange: targeting FXI anti-thrombus siRNA drug clinical phase II.
  IPO早知道 · 2025/4/27
• Rebio Biotech-B (06938.HK): Pipeline programs targeting FXI, APOC3, and others are advancing steadily, with multiple breakthroughs in extraliver technologies.
  Soochow Securities · 2026/5/19
• Funds are rapidly accumulating in overseas-listed Chinese asset ETFs, with KWEB, MCHI, and FXI attracting significant investment.
  Gelonghui Finance · 2025/8/20

Headlines are aggregated automatically and are not independently verified or edited by our team.